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OBJECTIVES: In Brazil, health insurance plans (HI) must pay for anticancer intra-
venous (IV) chemotherapy (CHEMO) but not for those taken by mouth (PO). Erlotinib
(E) is a PO CHEMO used to treat lung cancer 2nd or 3rd line. Our aim was to establish
the budgetary impact of the adoption of E, when compared to the IV competitors
docetaxel (D) and pemetrexed (P) for the HI in Brazil. METHODS: We searched
Evidencias Database for patients eligible for the use of E, in the year of 2008. This
database has information from 2 million of users of 14 HI. Then, we calculated the
costs of the IV chemo actually used. A simulation of the costs if E were adopted was
carried out. Many different sensitivity analyses were performed, according to the
line of treatment in which E was administered and the proportion changing from IV
to the PO option. RESULTS: We found 285 records of patients that were suitable for
the use of E. The cost of IV CHEMO was US$2,293,000. If E replaced the treatment for
all patients, the cost would be reduced to US$1,067,000, resulting in a economy of
US$1,222,000 (54%) of the total. If instead of replacing the IV option, E was used as
an additional line of treatment, an increase of US$635,000 in total costs would
occur. In a sensitivity analysis, that can reflect the practice, where 50% of the
patients would receive E instead of P or D in 2nd line, and 30% would receive E in 3rd
line, the adoption of E would result in an economy of US$295,000. CONCLUSIONS:
The adoption of E for the treatment of lung cancer in Brazil can be cost-saving for
HI.
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OBJECTIVES: To examine variation in real world health care utilization (HCU) and
costs associated with management of brain metastasis (BrMts) by primary malig-
nancy type. METHODS: A retrospective analysis utilized claims-data from a na-
tional health insurer, identifying patients18 yrs with2 claims7 days apart for
BrMets (ICD-9 198.3x) from January 2004 to April 2010. The index date was the date
of the first BrMets claim. Continuous enrollment (CE) in the health plan for 6
months before (baseline) and 1 month after (follow-up) index date was required;1
month follow-up was permitted if due to death. Excluding primary brain tumors,
baseline CE data (1993 to the index date) was examined to identify the initial pri-
mary malignancy. HCU (inpatient stays, office, outpatient and ER visits) and all-
cause per-patient per-month (PPPM) costs were examined. RESULTS: A total of
1031 lung and 395 breast cancer patients, and 93 with melanoma were included.
Baseline Charlson comorbidity score was not significantly different. Mean age at
BrRMets diagnosis was highest for lung (60yr) compared to breast cancer (55yr) and
melanoma (56yr)[p-value0.01]. Rates of HCU (events/person-month) were signif-
icantly different for melanoma, breast and lung cancer patients: 0.28 versus 0.17
and 0.24 for inpatient stays; 3.16 versus 3.87 and 3.94 for office visits; 2.84 vs. 2.69
and 2.80 for outpatient visits [p-value0.01]. Total costs PPPM were highest for
melanoma ($21,373) compared to breast ($17,933) and lung cancer ($15,199) [p-
value0.001]. Inpatient costs PPPM represented the largest portion of medical costs
(44%-50%), but were not significantly different across cohorts: melanoma ($9397),
breast ($8781) and lung cancer ($7628). Pharmacy costs PPPM were highest among
melanoma ($1555) then breast ($737) and lung cancer ($720) [p-value 0.001].
CONCLUSIONS: Variation was observed in HCU and costs among BrMets patients
based on initial primary tumor type. Analyses of cost studies on BrMets patients
need to take this into consideration.
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OBJECTIVES: To estimate direct costs associated to grades 3-4 adverse events (AEs)
management treatment of metastatic renal cell carcinoma (mRCC) with targeted
therapies (sorafenib, sunitinib, pazopanib, bevacizumab, everolimus and tem-
sirolimus) and to perform a comparative analysis from public and private health-
care perspectives, in Brazil. METHODS: A systematic literature review was con-
ducted to identify grades 3-4 AEs related to targeted therapies. To obtain direct
costs related to AEs management, procedures were created from national guide-
lines and expert validation. Total cost for each drug was calculated, considering a
six-month time horizon. Only direct medical costs were considered, expressed in
2011 Brazilian reals (BRL). Unit costs were obtained from Brazilian official lists. As
no head-to-head trials were found, indirect comparison in second-line targeted
therapy was performed according to NCCN guideline for everolimus (grade 1 rec-
ommendation) versus sorafenib and sunitinib (grade 2A) and temsirolimus (grade
2B). Bevacizumab (grade 2B) was excluded as data was available only for the asso-
ciation with IFN. In the base case, grades 3-4 incidence rates were obtained from
phase III clinical trials and varied in sensitivity analysis based on results obtained
in meta-analyses or observational studies. RESULTS: When compared to NCCN 2A
recommendation grade for second-line targeted therapy, everolimus is cost-saving
in base case and sensitivity analysis: versus sorafenib, there are savings ranging
from 5BRL to 717BRL and from 96BRL to 5841BRL in public and private perspectives,
respectively; versus sunitinib, savings vary from 153BRL to 681BRL and from
1778BRL to 5136BRL in public and private perspectives, respectively. Everolimus
was cost-saving due to easily manageable AEs and their frequencies.
CONCLUSIONS: Considering grades 1 and 2 NCCN recommendation for mRCC sec-
ond-line targeted therapies, everolimus represents the highest quality of evidence
and is also considered the lowest cost option for the management of associated AEs
from public and private healthcare perspectives, in Brazil.
PCN32
COST SAVINGS WITH BEVACIZUMAB COMPARED TO SUNITINIB IN THE
TREATMENT OF MRCC
Benkovic V1, Jelec D2, Antolic S3, Stevanovic R4
1Croatian society for pharmacoeconomics and Health Economics, Zagreb, Croatia, 2Roche Ltd,
Croatia, Zagreb, ZAGREB, Croatia, 3ROCHE d.o.o., ZAGREB, Croatia, 4Croatian Society for
Pharmacoeconomics and Health Economics, Zagreb, Croatia
OBJECTIVES: Assessing the adverse events costs of comparable regimens
(sunitinib vs bevacizumab) in context of budget impact analysis in Croatian setting.
METHODS: Authors have assessed costs and outcomes of bevacizumab and
sunitinib via systematic review, performed in January 2011. Survival rates, inci-
dence and prevalence was assessed via Croatian National Cancer Registry, and the
model was verified with Monte Carlo simulations. Direct drug, adverse events and
treatment costs were calculated in kuna/per patient yearly according to price list-
ings of National Institute for Health Insurance. Local data was verified with struc-
tured interviews gathered with Croatian oncologists (N6) involved in this indica-
tion in their daily practice. Focus of the analysis was the drug cost and the adverse
events treatment cost. RESULTS: Sunitinib has showed costly side effects such as
neutropenia, trombocitopenia, hypothiroidism and cardiovascular complications.
The cost of adverse events (aforementioned) for sunitinib per patient yearly is 3.904
HRK (535 EUR), whereas for bevacizumab is 1.404 HRK (192 EUR). Bevacizumab
demonstrated significantly lower adverse events costs than sunitinib. Overall bud-
get impact (from payers perspective) when bevacizumab is introduced equals
-29.753,52 HRK (-4075 EUR) of savings yearly per patient.CONCLUSIONS:At current
costs, head to head drug price comparison demonstrates that bevacizumab is less
costly, demonstrating dominant ability to reduce costs due to less frequent and
less costly adverse events, whereas in budget impact context introducing bevaci-
zumab brings savings.
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OBJECTIVES: Spaepen et al. (The Oncologist 2008;13:596–607) published a cost
analysis comparing darbepoetin-alfa (DARB), epoetin-alfa (EPO-A) and epoetin-
beta (EPO-B) in the treatment of chemotherapy-induced anaemia in 2393 patients.
Data were derived from the IMS Hospital Disease Database, a longitudinal database
in secondary care unique to Belgium. The objectives of this study were to assess the
applicability of that analysis in the Spanish setting, and to evaluate differences in
cost between ESAs in Spain. METHODS: To adapt the Belgian data for Spain, dis-
crepancies in epidemiology and treatment patterns were examined, and costs were
replaced with Spanish-specific unit costs. Adjusting for tumour-specific incidence
and chemotherapy use, costs were analyzed using a mixed-effects model stratify-
ing for propensity score quintiles as in Spaepen 2008. Data sources included Euro-
stat, national cancer registries, IMS sales data, treatment guidelines, and reim-
bursement guidelines and lists. RESULTS: The Spanish and Belgian populations
were similar in terms of age, gender, ESA use and blood transfusions. Adjusting for
chemotherapy use and the relative weight (incidence Spain/ incidence Belgium) of
four pre-specified cancer types [haematological (1.2094), lung (0.6716), female
breast (0.5654) and female genital (0.9589)], total costs (meanSE) with DARB were
26% lower compared with EPO-A (p0.0001) and 20% lower compared with EPO-B
(p0.0019). Anaemia-related costs were 29% and 17% lower in DARB patients than
in EPO-A (p0.0001) and EPO-B (p0.0226) respectively. The mean duration of treat-
ment was 40.632.39 days for DARB; 53.591.25 for EPO-A and 52.392.54 for
EPO-B. CONCLUSIONS: By using published epidemiologic and treatment pattern
data, it was possible to adapt the Belgian Hospital database to the Spanish popu-
lation. Total and anaemia-related costs were lowest in patients receiving DARB
compared with EPO-A or EPO-B. These findings are consistent with those from the
Belgian analysis.
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OBJECTIVES: Spaepen et al. (the Oncologist 2008;13:596–607) published a cost-
analysis comparing darbepoetin-alfa (DARB), epoetin-alfa (EPO-A) and epoetin-
beta (EPO-B) in the treatment of chemotherapy-induced anaemia, using propensity
score matching. The study was performed using IMS Hospital Disease Database
(2003-2005, a longitudinal database unique to Belgium containing individual pa-
tient/admission-level data on diagnoses, procedures, and pharmaceuticals. Given
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